Abstract:Tumorigenesis is a complex and dynamic process involving cell-cell and cell-extracellular matrix (ECM) interactions that allow tumor cell growth, drug resistance and metastasis. This review provides an updated summary of the role played by the tumor microenvironment (TME) components and hypoxia in tumorigenesis, and highlight various ways through which tumor cells reprogram normal cells into phenotypes that are pro-tumorigenic, including cancer associated- fibroblasts, -macrophages and -endothelial cells. Tumor cells secrete numerous factors leading to the transformation of a previously anti-tumorigenic environment into a pro-tumorigenic environment. Once formed, solid tumors continue to interact with various stromal cells, including local and infiltrating fibroblasts, macrophages, mesenchymal stem cells, endothelial cells, pericytes, and secreted factors and the ECM within the tumor microenvironment (TME). The TME is key to tumorigenesis, drug response and treatment outcome. Importantly, stromal cells and secreted factors can initially be anti-tumorigenic, but over time promote tumorigenesis and induce therapy resistance. To counter hypoxia, increased angiogenesis leads to the formation of new vascular networks in order to actively promote and sustain tumor growth via the supply of oxygen and nutrients, whilst removing metabolic waste. Angiogenic vascular network formation aid in tumor cell metastatic dissemination. Successful tumor treatment and novel drug development require the identification and therapeutic targeting of pro-tumorigenic components of the TME including cancer-associated- fibroblasts (CAFs) and -macrophages (CAMs), hypoxia, blocking ECM-receptor interactions, in addition to the targeting of tumor cells. The reprogramming of stromal cells and the immune response to be anti-tumorigenic is key to therapeutic success. Lastly, this review highlights potential TME- and hypoxia-centered therapies under investigation.

Tumor microenvironment promotes breast cancer chemoresistance

The tumor microenvironment: a key player in multidrug resistance in cancer

Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer

Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance

Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis

The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer

Cancer Stem Cells and the Tumor Microenvironment in Tumor Drug Resistance

Messing Up the Cancer Stem Cell Chemoresistance Mechanisms Supported by Tumor Microenvironment

Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment

The Role of TAMs in the Regulation of Tumor Cell Resistance to Chemotherapy

Unraveling the Tumor Microenvironment: Insights into Cancer Metastasis and Therapeutic Strategies

Cytokines, Breast Cancer Stem Cells (bcscs) and Chemoresistance

The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment

Tumor Microenvironment: From Cervical Carcinogenesis to Therapeutic Advancements

Tumour Microenvironment Stress Promotes the Development of Drug Resistance

The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited

Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics

Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer

The tumor microenvironment: shaping cancer progression and treatment response